Agenda

Please note that all times listed currently reflect US Eastern Time (ET). The schedule is subject to change.

Presentations are live or pre-recorded followed by live group Q&A.

Wednesday, July 21, 2021
 
Time Event
8:30 am – 8:45 am Welcome and Introductions:
Kathrin Bernt (Children's Hospital of Philadelphia) and Michael Kharas (Memorial Sloan Kettering Cancer Center)
8:45 am – 9:30 am Keynote Address: Catherine Wu (Dana Farber Cancer Institute, Boston, USA)
Genomic heterogeneity of CLL: from patients to the bench and back again
9:30 am – 9:45 am Break
9:45 am – 12:00 pm Stem and Progenitor Cell Biology
Moderator 1: Vijay Sankaran (Boston Children's Hospital, USA)
Moderator 2: Britta Will (Albert Einstein College of Medicine, USA)
9:45 am – 10:05 am Vijay Sankaran (Boston's Children's Hospital, USA)  
Inherited blood cancer predisposition through altered transcription elongation
10:05 am – 10:25 am Marie-Dominique Filippi (Cincinnati Children's Hospital, USA)
TBD
10:25 am – 10:35 am Alejo E. Rodriguez Fraticelli (Institute for Research in Biomedicine, Barcelona, Spain)
Single-cell lineage tracing of wild-type, aged and preleukemic HSCs
10:35 am – 10:45 am Short Talk: Ly Vu (Simon Fraser University/British Columbia Cancer Agency)
RNA binding protein SYNCRIP is required for the low-output HSC by sustaining proteome quality
10:45 am – 11:00 am Questions & Answers
11:00 am – 11:20 am Lenoard Zon (Boston Children's Hospital, USA)
Differential resistance to inflammation underlies enhanced fitness in clonal hematopoiesis
11:20 am – 11:30 am Britta Will (Albert Einstein College of Medicine, USA)
Chaperone-mediated autophagy safeguards hematopoietic stem cells
11:30 am – 11:45 am Atsushi Iwama (The Institute of Medical Sciences University of Tokyo, Japan)
Non-canonical PRC1 regulates homeostatic and emergency hematopoiesis by restricting myeloid differentiation program
11:40 am – 11:50 am Short Talk: Vikram Paralkar (University of Pennsylvania)
An Atlas of Hematopoietic Transcription Factor binding to Ribosomal DNA Reveals a Role for CEBPA in Regulation of rRNA Transcription
11:50 am – 12:00 pm Questions and Answers
12:00 pm – 1:15 pm Lunch
12:15 pm – 1:15 pm Career Development Workshop - Catherine Wu, (Dana Farber Cancer Institute, Boston, USA), Adolfo Ferrando (Columbia University, NYC, USA), Marieke Essers (Heidelberg Institute for Stem Cell Technology and Experimental Medicine, Germany), and Dave Barrett (Tmunity Therapeutics)
1:35 pm – 3:20 pm Lymphoid Malignancy Biology
Moderator 1: Ari Melnick (Weill Cornell NYC, USA)
Moderator 2: Margarida Albuquerque Almeida Santos (MD Anderson, Houston, USA)
1:35 pm – 1:55 pm Ari Melnick (Weill Cornell NYC, USA)
Novel Mechanisms of Lymphomagenesis
1:55 pm – 2:05 pm Alejandro Gutierrez: (Boston Children's Hospital, Boston, USA)
Supramolecular Assembly of GSK3α as a Cellular Response to Asparagine Starvation
2:05 pm – 2:15 pm Short Talk: Luca Tottone (Rutgers Cancer Institute of New Jersey - CINJ)
A Tumor Suppressor Enhancer of PTEN in T-cell development and leukemia
2:15 pm – 2:30 pm Questions and Answers
2:30 pm – 2:50 pm Charles Mullighan (St. Jude Children's Hospital, Memphis, USA)
Genetic basis of lineage ambiguous leukemia
2:50 pm – 3:00 pm Brian Walker (University of Indiana, Indianapolis, USA)
High Risk Genomics Markers of Progression from Smoldering to Active Myeloma
3:00 pm – 3:10 pm Markus Müschen (Yale University, USA)
Mechanisms of central tolerance as therapeutic targets in B-cell malignancies
3:10 pm – 3:20 pm Questions and Answers
3:20 pm – 3:45 pm Poster Teasers (1 minute talks)
Kristina Ames (Albert Einstein College of Medicine)
PI3-Kinase Deletion Dysregulates Autophagy in HSCs and Promotes Myelodysplasia
Yoon-A Kang (Columbia University Irving Medical Center)
Secretory MPP3 enforce myeloid differentiation trajectory and amplify myeloid cell production
Dinesh Rao (UCLA)
Regulation of MLL-AF4 mediated leukemogenesis by IGF2BP3
Giada Bianchi (Brigham and Women's Hospital)
Multiple Myeloma Cells Depend on the DDI2/NRF1-mediated Proteasome Stress Response for Survival
Anna-Katharina Wirth (Helmholtz Zentrum München)
Acquired resistance in PDX ALL in vivo reveals distinct genomic alterations, but identical dysregulated therapeutic target genes
Alan Cantor (Boston Children's Hospital/Dana-Farber Cancer Institute)
Germline GATA1 mutations associated with familial predisposition to myeloid neoplasm with acquired trisomy 21 and Myeloid Leukemia of Down Syndrome-like phenotype
Maria Aivalioti (Albert Einstein College of Medicine)
PU.1-dependent enhancer decommissioning separates clonal hematopoiesis from malignant transformation
Brooks Benard (Stanford University)
Clonal architecture is associated with clinical outcomes and drug response in acute myeloid leukemia
Hossein Khiabanian (Rutgers University)
Adaptation of chronic lymphocytic leukemia to ibrutinib is mediated by epigenetic plasticity of residual disease and by-pass signaling via MAPK pathway
Yoshitaka Sunami (The Cancer Institute, Japanese Foundation for Cancer Research)
BCL11A promotes myeloid leukemogenesis by abrogating transcriptional activity of PU.1
Olga Guryanova (University of Florida College of Medicine)
Clonal Hematopoiesis Driven by Partial Ablation of Dnmt3a Contributes to an Aggressive Colon Cancer Phenotype
Lisa Russell (Newcastle University)
Computational simulations shed light on the 3D consequence of super-enhancer hijacking in B-cell malignancies
Francine Garrett-Bakelman (University of Virginia)
Gene expression profiles reveal distinct transcriptional regulatory activities in relapsed AML
Maxim Pimkin (Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School)
Transcriptional immunoediting of AML cells after allogeneic stem cell transplantation
3:45 pm – 5:00 pm Poster Session/Poster Tiles
5:00 pm – 6:00 pm Game Night
 

Thursday, July 22, 2021
 
Time Event
8:30 am – 8:45 am Day Two: Welcome Address: Kathrin Bernt and Michael Kharas
8:45 am – 9:30 am Keynote Speaker #2: Adolfo Ferrando (Columbia University, NYC, USA)
TBD
9:30 am – 9:45 am Break
9:45 am – 12:00 pm Myeloid Neoplasms and Malignancies
Moderator #1:Elli Papaemmanuil (Memorial Sloan Kettering Cancer Center, USA)
Moderator #2: Kira Gritsman (Albert Einstein College of Medicine, USA)
9:45 am – 10:05 am Elli Papaemmanuil (Memorial Sloan Kettering Cancer Center, USA)
TBD
10:05 am – 10:15 am Peter Van Galen (Brigham and Womens Hospital, Boston, USA)
Mitochondrial Variant Enrichment From High-Throughput Single Cell RNA-seq Resolves Clonal Populations
10:15 am – 10:25 am Liran Shlush (Weizmann Institute of Science, Israel)
Recurrent deletions in clonal hematopoiesis are driven by Microhomology-mediated end joining
10:25 am – 10:35 am Short Talk: Linde Miles (Memorial Sloan Kettering Cancer Center)
Clonotype-Immunophenotype Relationships in TET2 and IDH1/2-Mutant Myeloid Transformation
10:35 am – 10:50 am Questions and Answers
10:50 am – 11:10 am Ulrich Steidl (Albert Einstein College of Medicine, USA)
Stem Cell Heterogeneity and Transcriptional Plasticity in Normal and Malignant Hematopoiesis
11:10 am – 11:20 am Ann Mullally (Brigham and Womens Hospital, USA)
Rationally Designed Approaches to Treat Pre-Clinical and Overt MPN
11:20 am – 11:30 am Florian Heidel (Universitätsmedizin Greifswald, Germany)
TBD
11:30 am – 11:40 am Short Talk: Eirini Papapetrou (Icahn School of Medicine at Mount Sinai)
Integrative mRNA binding and splicing analysis identifies altered GNAS isoform usage as a phenotypic driver in splicing factor mutant neoplasms 
11:40 am – 11:50 am Short Talk: Ruud Delwel (Erasmus MC Cancer Institute)
Enhancer driven oncogene activation in leukemia
11:50 am – 12:00 pm Questions and Answers
12:00 pm – 12:15 pm Break
12:15 pm – 12:45 pm Meet the Editors - Alexia Zaromytidou, Nature Cancer; Tanya Bondar, Blood Cancer Discovery; Krista Bledsoe, Molecular Cell; Cindy Sun, Journal of Experimental Medicine; and Michele Hartsough, Cancer Discovery
12:45 pm – 1:00 pm Break
1:00 pm – 2:45 pm Inflammation and the Leukemic Niche
Moderator #1: Emmanuelle Passegue (Columbia University NYC, USA)
Moderator #2: Trista North (Boston Children's Hospital, USA)
1:00 pm – 1:20 pm Emmanuelle Passegue (Columbia University, NYC, USA)
Emergency Myelopoiesis in the Pathogenesis of Myeloid Malignancies
1:20 pm – 1:30 pm Trista North (Boston Children's Hospital, USA)
Extrinsic regulation of vertebrate hemogenic endothelium specification and HSPC production
1:30 pm – 1:40 pm Short Talk: Mona Mohammadhosseini (Oregon Health and Science University)
The impact of germline RUNX1 mutations mediated transcriptomic changes and inflammatory microenvironment on hematopoiesis in Familial Platelet Disorder
1:40 pm – 1:55 pm Questions and Answers
1:55 pm – 2:15 pm Marieke Essers (Heidelberg Institute for Stem Cell Technology and Experimental Medicine, Germany)
Inflammation-responding Mesenchymal Stromal Cells modulate the bone marrow microenvironment response to stress over time
2:15 pm – 2:25 pm Marc Raaijmakers (Erasmus Cancer Institute, Rotterdam Netherlands)
Stromal inflammation and clonal evolution in MDS
2:25 pm – 2:35 pm Kelly Bolton (Washington University St. Louis, USA)
TBD
2:35 pm – 2:45 pm Questions and Answers
2:45 pm – 3:00 pm Break
3:00 pm – 4:40 pm Targeted Therapy
Moderator #1: Benjamin Ebert (Dana Farber Cancer Institute, Boston, USA)
Moderator #2: Monica Guzman (Weill Cornell, NYC, USA)
3:00 pm – 3:20 pm Benjamin Ebert (Dana Farber Cancer Institute, USA)
TBD
3:20 pm – 3:30 pm Monica Guzman (Weill Cornell, NYC, USA)
TBD
3:30 pm – 3:40 pm Short Talk: Samuel Taylor (Albert Einstein College of Medicine)
Pharmacologically-induced transcription factor re-PU-sitioning in AML
3:40 pm – 3:50 pm Questions and Answers
3:50 pm – 4:00 pm Short Talk: Maria Moscvin (Brigham and Women's Hospital)
Targeting Free Light Chain Secretion via Botulinum Neurotoxin is a Novel Therapeutic Strategy in AL amyloidosis by Inducing a Terminal Unfolded Protein Response
4:00 pm – 4:10 pm Leslie Crews (University of California, San Diego, USA)
Detecting and targeting IRF4 to prevent malignant regeneration in multiple myeloma
4:10 pm – 4:20 pm Short Talk: Prerna Malaney (MD Anderson Cancer Center)
Harnessing Mechanistic Insights to Target the Oncogenic Functions of hnRNP K
4:20 pm – 4:40 pm Questions and Answers
4:40 pm – 5:00 pm Closing Comments and Business Meeting: Kathrin Bernt and Michael Kharas